These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27264077)

  • 1. Corrigendum to 'A preoperative personalized risk assessment calculator for elderly ovarian cancer patients undergoing primary cytoreductive surgery' Gynecol. Oncol. 139 (2015) start 401-406.
    Barber EL; Rutstein SE; Miller WC; Gehrig PA
    Gynecol Oncol; 2016 Aug; 142(2):380. PubMed ID: 27264077
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "The sooner the better: Genetic testing following ovarian cancer diagnosis" [Gynecol. Oncol. 137 (2015) 423-429].
    Fox E; McCuaig J; Demsky R; Shuman C; Chitayat D; Maganti M; Murphy J; Rosen B; Ferguson S; Randall Armel S
    Gynecol Oncol; 2017 May; 145(2):409. PubMed ID: 28256319
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to 'Equivalency challenge: evaluation of Lipodox® as the generic equivalent for Doxil® in a human ovarian cancer orthotropic mouse model' [Gynecol. Oncol. 141 (2016) 357-363].
    Smith JA; Mathew L; Burney M; Nyshadham P; Coleman RL
    Gynecol Oncol; 2017 Feb; 144(2):448. PubMed ID: 28089052
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA
    Gynecol Oncol; 2019 Jan; 152(1):220. PubMed ID: 30360899
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Naumann RW; Coleman RL; Brown J; Moore KN
    Gynecol Oncol; 2020 Feb; 156(2):512-513. PubMed ID: 31859001
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictors of surgical outcome and survival among elderly women diagnosed with ovarian and primary peritoneal cancer.
    Alphs HH; Zahurak ML; Bristow RE; Díaz-Montes TP
    Gynecol Oncol; 2006 Dec; 103(3):1048-53. PubMed ID: 16876237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis.
    Bristow RE; Puri I; Chi DS
    Gynecol Oncol; 2009 Jan; 112(1):265-74. PubMed ID: 18937969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corrigendum to "Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center" [Gynecol. Oncol. 142 (2016) 13-18].
    Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
    Gynecol Oncol; 2016 Oct; 143(1):225. PubMed ID: 27496397
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil® in frontline maintenance" [Gynecol. Oncol. Rep. 34 (2020) 100648].
    Oh J; Barve M; Senzer N; Aaron P; Manning L; Wallraven G; Bognar E; Stanbery L; Horvath S; Manley M; Nemunaitis J; Walter A; Rocconi RP
    Gynecol Oncol Rep; 2021 May; 36():100740. PubMed ID: 34095420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corrigendum to "Metastatic hepatoid carcinoma of ovarian origin - A case report from Northern Pakistan" [Gynecol. Oncol. Rep. 21 (2017) 24-27].
    Mahmood H; Fatima H; Faheem M
    Gynecol Oncol Rep; 2017 Nov; 22():117. PubMed ID: 29296656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corrigendum to "Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer" [Gynecol. Oncol. 141 (2016) 588-591].
    Frumovitz M; Burzawa JK; Byers LA; Lyons YA; Ramalingam P; Coleman RL; Brown J
    Gynecol Oncol; 2016 Oct; 143(1):224. PubMed ID: 27477189
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448].
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2020 May; 157(2):558-559. PubMed ID: 32087992
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" Gynecol. Oncol. 154 (2019) 441-448.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2021 Apr; 161(1):328-329. PubMed ID: 33551198
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to 'Tumor diameter as a predictor of lymphatic dissemination in endometrioid endometrial cancer' [Gynecol. Oncol. 141 (2016) 199-205].
    Cox Bauer CM; Greer DM; Kram JJF; Kamelle SA
    Gynecol Oncol; 2017 Mar; 144(3):649. PubMed ID: 28131527
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Chemoradiation versus chemotherapy or radiation alone in stage III endometrial cancer: Patterns of care and impact on overall survival" [Gynecol. Oncol. 141 (2016) 421-427].
    Boothe D; Orton A; Odei B; Stoddard G; Suneja G; Poppe MM; L Werner T; Gaffney DK
    Gynecol Oncol; 2016 Dec; 143(3):690-691. PubMed ID: 27726921
    [No Abstract]   [Full Text] [Related]  

  • 16. Cytoreductive surgery for patients with recurrent epithelial ovarian carcinoma.
    Tebes SJ; Sayer RA; Palmer JM; Tebes CC; Martino MA; Hoffman MS
    Gynecol Oncol; 2007 Sep; 106(3):482-7. PubMed ID: 17590420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corrigendum to "HPV vaccines-A review of the first decade" [Gynecol. Oncol. 146 (2017) 196-204].
    Harper DM; DeMars LR
    Gynecol Oncol; 2017 Nov; 147(2):489. PubMed ID: 28844538
    [No Abstract]   [Full Text] [Related]  

  • 18. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma.
    Chi DS; Zivanovic O; Palayekar MJ; Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Leitao MM; Brown CL; Barakat RR
    Gynecol Oncol; 2009 Jan; 112(1):6-10. PubMed ID: 19100916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diaphragm resection for ovarian cancer: technique and short-term complications.
    Cliby W; Dowdy S; Feitoza SS; Gostout BS; Podratz KC
    Gynecol Oncol; 2004 Sep; 94(3):655-60. PubMed ID: 15350355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corrigendum to 'Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women' [Gynecol. Oncol. 143 (2016) 128-134].
    Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
    Gynecol Oncol; 2017 Jan; 144(1):227. PubMed ID: 27884515
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.